Emilio Francesco Giunta1, Margaret Ottaviano2,3, Alessandra Mosca4, Giuseppe Luigi Banna5, Pasquale Rescigno6. 1. Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy. 2. Oncology Unit, Ospedale del Mare, Naples, Italy. 3. CRCTR Coordinating Rare Tumors Reference Center of Campania Region, Naples, Italy. 4. Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy. 5. Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth PO2 8QD, UK. 6. Interdisciplinary Group for Translational Research and Clinical Trials, Urological Cancers (GIRT-Uro), Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
Abstract
Objective: The aim of this review is to analyze feasibility and toxicities of high-dose chemotherapy (HDCT) in comparison to standard dose chemotherapy (SDCT) in patients affected by mediastinal germ cell tumors (MGCTs), discussing factors that may affect therapeutic choices, such as: management of residual disease, early response predictors for chemotherapeutic efficacy and determinants of chemotherapeutic resistance. In this review, we discuss the main clinical experiences with HDCT and SDCT in germ cell tumor (GCT) patients specifically in those affected by MGCT. Background: MGCTs represent a very small subset characterized by a poor prognosis, despite improvements in their clinical management and in understanding their biology. From early 1970s, HDCT has become an alternative to SDCT for both first-line and salvage therapeutic settings in advanced GCT patients. Several HDCT schedules-either cisplatin or carboplatin-based-have been tested so far, both in clinical randomized trial and in single-center experiences, with divergent results in terms of clinical outcomes and tolerability. Moreover, the majority of these studies included, but were not exclusively designed for, advanced MGCT patients, making difficult to infer data for this specific subset. Methods: an extended review of literature through PubMed was conducted using the keywords "mediastinal germinal cell tumors", "standard dose chemotherapy" and "high dose chemotherapy". Conclusions: HDCT regimens could not be considered to date a standard option as first-line therapy in advanced MGCT patients, whilst they could be an alternative to SDCT regimens in relapsed tumors after proper patient selection. 2022 Mediastinum. All rights reserved.
Objective: The aim of this review is to analyze feasibility and toxicities of high-dose chemotherapy (HDCT) in comparison to standard dose chemotherapy (SDCT) in patients affected by mediastinal germ cell tumors (MGCTs), discussing factors that may affect therapeutic choices, such as: management of residual disease, early response predictors for chemotherapeutic efficacy and determinants of chemotherapeutic resistance. In this review, we discuss the main clinical experiences with HDCT and SDCT in germ cell tumor (GCT) patients specifically in those affected by MGCT. Background: MGCTs represent a very small subset characterized by a poor prognosis, despite improvements in their clinical management and in understanding their biology. From early 1970s, HDCT has become an alternative to SDCT for both first-line and salvage therapeutic settings in advanced GCT patients. Several HDCT schedules-either cisplatin or carboplatin-based-have been tested so far, both in clinical randomized trial and in single-center experiences, with divergent results in terms of clinical outcomes and tolerability. Moreover, the majority of these studies included, but were not exclusively designed for, advanced MGCT patients, making difficult to infer data for this specific subset. Methods: an extended review of literature through PubMed was conducted using the keywords "mediastinal germinal cell tumors", "standard dose chemotherapy" and "high dose chemotherapy". Conclusions: HDCT regimens could not be considered to date a standard option as first-line therapy in advanced MGCT patients, whilst they could be an alternative to SDCT regimens in relapsed tumors after proper patient selection. 2022 Mediastinum. All rights reserved.
Authors: Anja Lorch; Caroline Bascoul-Mollevi; Andrew Kramar; Lawrence Einhorn; Andrea Necchi; Christophe Massard; Ugo De Giorgi; Aude Fléchon; Kim Margolin; Jean-Pierre Lotz; Jose Ramon Germà-Lluch; Thomas Powles; Christian Kollmannsberger; Jörg Beyer Journal: J Clin Oncol Date: 2011-03-28 Impact factor: 44.544
Authors: Maria G Kier; Jakob Lauritsen; Mette S Mortensen; Mikkel Bandak; Klaus K Andersen; Merete K Hansen; Mads Agerbaek; Niels V Holm; Susanne O Dalton; Christoffer Johansen; Gedske Daugaard Journal: Eur Urol Date: 2016-09-17 Impact factor: 20.096
Authors: Giovanni Rosti; Simona Secondino; Andrea Necchi; Giuseppe Fornarini; Paolo Pedrazzoli Journal: Semin Oncol Date: 2019-04-24 Impact factor: 4.929
Authors: C Bokemeyer; N Schleucher; B Metzner; M Thomas; O Rick; H-J Schmoll; C Kollmannsberger; I Boehlke; L Kanz; J T Hartmann Journal: Br J Cancer Date: 2003-07-07 Impact factor: 7.640